Search

Recent discoveries in Yunnan province have confirmed the presence of the Hoabinhian technocomplex in this southern part of China. Compared with the history of Hoabinhian research in Southeast Asia, which goes back almost a century with numerous Hoabinhian sites dating back to the late Upper Pleistocene and Holocene, southwest China is still a blank page on the Hoabinhian question until recent years. For the vast territory of Yunnan (394,000 km2), we currently have only two published ancient Hoabinhian sites (Xiaodong rockshelter and Dedan cave) with reliable dating and typo-technological studies. To test the "Chinese Hoabinhian Homeland" hypothesis and the geo-strategic importance of Yunnan in migration routes to Southeast Asia, proposed in previous studies, modern archaeological methods should enable more sites in these southern Chinese regions to be discovered, excavated and studied. Firstly, fieldwork carried out in southwestern Yunnan in recent years (investigation, prospecting, excavation, etc.), where numerous lithic artefacts with Hoabinhian affinities have been collected, is discussed. The aim of this article is to present the typo-technological composition of these unpublished lithic assemblages from nine caves and open-air localities. Although we do not yet have precise stratigraphic information, their presence could nonetheless confirm the presence of the Hoabinhian lithic tradition in this region located in the upper reaches of the Mekong and Salween rivers within the most northerly humid tropical forest environment in Southeast Asia. Finally, we will discuss the diffusion strategy of Hoabinhian settlements in East Asia in a specific environmental and geographical context, as well as their possible dispersal along the river routes that irrigate and structure the relief of Southwest China and Peninsular Asia. [ABSTRACT FROM AUTHOR]

Background: The 2023 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) antiphospholipid syndrome (APS) classification criteria were developed with higher specificity but lower sensitivity compared with the 2006 Sydney revised classification criteria., Objectives: To validate the performance of the 2023 ACR/EULAR APS classification criteria in a large Chinese APS cohort., Methods: This was a single-center cohort study. Inclusion criteria aligned with the entry criteria of 2023 criteria. APS classification by "expert consensus panel" served as the gold standard. Sensitivity and specificity were compared between the 2023 and 2006 criteria., Results: A total of 526 patients with a mean age of 38.55 ± 12.67 years were enrolled, of whom 366 (69.58%) were female and 182 (34.60%) had systemic lupus erythematosus (SLE). Among them, 407 (77.38%) patients were classified as APS by experts. The 2023 criteria demonstrated higher overall specificity than the 2006 criteria (0.983 vs 0.950), while sensitivity was relatively lower (0.818 vs 0.853). The sensitivity of the 2023 criteria improved for patients with SLE (0.860 vs 0.825), microvascular manifestations (0.867 vs 0.786), cardiac valve disease (0.903 vs 0.774), and thrombocytopenia (0.811 vs 0.790). Reduced sensitivity of the 2023 criteria was linked to the omission of certain microvascular manifestations, a stricter definition of pregnancy morbidity, and the exclusion of isolated thrombocytopenia and isolated IgM isotype antiphospholipid antibodies from meeting clinical and laboratory criteria, respectively., Conclusion: The 2023 criteria offer higher overall specificity and improved sensitivity in specific patient subsets, such as those with SLE, microvascular manifestations, cardiac valve disease, and thrombocytopenia when compared with the 2006 criteria., Competing Interests: Declaration of competing interests There are no competing interests to disclose., (Copyright © 2024 International Society on Thrombosis and Haemostasis. All rights reserved.)